

A Prospective Study of ^{18}F -DFA PET Imaging for the Assessment of Liver Injury

NCT07050550

Status	RECRUITING
Sponsor	First Affiliated Hospital of Zhejiang University
Enrollment	45 participants

Key Eligibility Criteria

Inclusion (1)

- 1) Aged between 18 and 80 years old; 2) Clinically diagnosed with liver damage (combined with medical history and laboratory tests, manifested as changes in liver enzymes, abnormal bilirubin metabolism, dysfunction of substance synthesis, and decreased biodegradation function, including indicators such as ALT, AST, ALP, GGT, albumin (Alb), TBil, and DBil); 3) Clinically diagnosed with liver failure (liver failure is a severe liver damage caused by multiple factors, resulting in severe dysfunction or decompensation of its synthesis, detoxification, excretion, and biotransformation functions, and a group of clinical syndromes with coagulation dysfunction, jaundice, hepatic encephalopathy, ascites, etc. as the main manifestations. Key points for the diagnosis of liver failure (a) Extreme fatigue, and severe gastrointestinal symptoms such as anorexia, vomiting, and abdominal distension; (b) Progressive deepening of jaundice (serum TBil $\geq 17.1\mu\text{mol/L}$ or daily increase $\geq 17.1\mu\text{mol/L}$); (c) Bleeding tendency, plasma prothrombin activity (PTAd40% or international normalized ratio (INR) ≥ 1.5 ; (d) hepatic encephalopathy (grade II or above) or other complications.); 4) informed consent and able to accept follow-up, can understand and comply with the requirements of the study

Exclusion (1)

- 1) Patients with serious primary diseases of the heart, brain, kidney and hematopoietic system (i.e. Weber heart function grade D; hemoglobin (Hb) $< 10\text{ g/dL}$, white blood cells (WBC) $< 3 \times 10^9/\text{L}$, platelets (PLT) $< 90 \times 10^9/\text{L}$; creatinine clearance (CrCl) $< 40\text{ mL/min}$); 2) Patients with mental disorders or primary affective disorders; 3) Patients who cannot understand, follow the study protocol or sign the informed consent form; 4) Patients with contraindications to PET imaging (including pregnant women, breastfeeding women, women of childbearing age who have plans to have children in the near future, etc.); 5) Patients with allergies to imaging agents; 6) Patients who cannot cooperate with PET scanning due to hypoglycemia, severe pain or tremor.

Locations (1 total)

The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hangzhou, Zhejiang, China

<https://clinicaltrials.gov/study/NCT07050550>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.